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a b s t r a c t
Case: A 73-year-old immunocompromised male presented with recurrent left elbow swelling due to My-
cobacterium avium intracellulare complex (MAC) olecranon bursitis. 3 years after completing MAC treatment,
he underwent right total knee arthroplasty (TKA). 1 year later, he developed TKA pain and swelling and was
diagnosed with MAC prosthetic joint infection (PJI). He underwent TKA resection, reimplantation, and 12
months of anti-MAC therapy. This patient is the seventh case report of MAC olecranon bursitis and the third
case report of MAC PJI. He is the only report of both MAC olecranon bursitis and PJI occurring in the same
patient.
Informed consent: This patient was informed and agreed to the publication of this material.
© 2015 Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Nontuberculous mycobacteria (NTM) comprise over 125 species
nd are ubiquitous in soil, water, and animals. Mycobacterium avium
ntracellulare complex (MAC) is the most common pathogenic NTM
pecies and consists of M. avium and M. intracellulare, which are in-
istinguishable based on traditional laboratory testing. MAC usually
auses pulmonary disease but may also cause lymphatic, skin/soft
issue, skeletal, or disseminated disease. Water sources, such as re-
irculating hot-water systems, are the reservoir for most MAC infec-
ions.[1] We illustrate a rare case of MAC causing both olecranon bur-
itis and prosthetic joint infection (PJI) in an immunocompromised
ost.
ase report
A 73-year-old male with history of multiple myeloma (in remis-
ion for 3 years after thalidomide and dexamethasone treatment) and
hronic cough, presented to the Emergency Department with 3 days
f left elbow swelling, which was diagnosed as olecranon bursitis∗ Corresponding author. Tel.: +1 507 284 9456.
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ory of elbow trauma. His bursitis improved with a steroid injection
ut recurred 2 months later and was treated with a repeat steroid in-
ection. Unfortunately, his bursitis recurred again 2 months later, and
ursa aspirate yielded a white blood cell (WBC) count of 45,708 with
8% neutrophils, suspicious for septic bursitis. Bacterial cultures were
egative, and he had not been on antibiotics previously. He received
14-day course of cephalexin.
Because the elbow was still edematous after 8 days of cephalexin,
e underwent elbow debridement, which revealed purulent ﬂuid
ith erythematous grayish-brown tissue. Histology showed acutely
nﬂamed synovium consistent with infection. 2 out of 3 samples were
mear-positive for acid-fast bacilli. All 3 operative mycobacterial cul-
ures and the initial aspiration grew MAC.
On review of systems, he mentioned a chronic productive cough.
he patient smoked a pipe for 10 years but quit 65 years ago. He had
o formal diagnosis of COPD. Sputum cultures grew MAC. A chest X-
ay showed basal atelectasis and multiple bilateral calciﬁed pleural
laques, consistent with prior asbestos exposure (Fig. 2). There was
o signiﬁcant change compared to a chest X-ray done 3 years prior to
resentation, and tuberculosis skin testing was negative. Other expo-
ures included gardening, hot-tub use, and a pet dog.
The MAC isolate was susceptible to rifabutin, ethambutol, and
larithromycin; intermediate to rifampin, streptomycin, and mox-
ﬂoxacin; and resistant to ciproﬂoxacin, kanamycin, cycloserine,
thionamide, and amikacin. His initial treatment regimen included
larithromycin 500 mg PO BID, ethambutol 1600 mg PO daily, andC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Left elbow X-ray (left panel: lateral view, right panel: anteroposterior view) shows soft tissue swelling (red arrow) overlying the extensor surface of the olecranon, consistent
with olecranon bursitis. There is also a tiny olecranon spur and minimal bone spurring at both humeral epicondyles. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article).
Fig. 2. Anteroposterior view of chest X-ray shows basal atelectasis and multiple bilateral calciﬁed pleural plaques (red arrow) consistent with prior asbestos exposure. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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ﬂrifabutin 300 mg once daily. The rifabutin was discontinued 3 weeks
into therapy due to neutropenia and transaminitis. His bursitis re-
solved after a 12-month course of ethambutol and clarithromycin. Re-
peat sputum cultures were not obtained after completion of therapy.
One year later, his multiple myeloma recurred, and he was started
on lenalidomide and dexamethasone. Around this time, he was also
diagnosed with seronegative rheumatoid arthritis (RA) and initiated
methotrexate. 3 years after completing his MAC treatment, he un-erwent an elective right total knee arthroplasty (TKA) for degener-
tive joint disease. This procedure was performed at an outside fa-
ility with presumed peri-operative prophylaxis. One year later, he
eveloped right TKA pain, instability, and swelling. X-ray showed a
ell-seated right TKA with a large effusion (Fig. 3). C-reactive protein
CRP) was elevated at 13.5 mg/L (reference range < 8 mg/L), and ery-
hrocyte sedimentation rate (ESR) was elevated at 65 mm/h. Synovial
uid aspiration yielded 4524 total nucleated cells; 57% neutrophils,
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Fig. 3. Right knee X-ray shows a well-seated TKA with large effusion or synovitis (red arrow). Left panel shows an anteroposterior view of the standing knee. Right panel shows a
lateral view of the knee in ﬂexion. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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tnd 39% monocytes. The synovial ﬂuid aspirate grew MAC. He un-
erwent TKA resection with placement of a vancomycin/tobramycin
mpregnated spacer. Histology was negative for acute inﬂammation
r granulomas. All 4 surgical tissue samples grew MAC. His multiple
yeloma chemotherapy and methotrexate for RA were held.
His TKA MAC isolate was still susceptible to ethambutol and
larithromycin. Although it was previously susceptible to rifabutin,
t now demonstrated intermediate susceptibility. He was initially
tarted on clarithromycin, ethambutol and rifabutin, but due to recur-
ent transaminitis and neutropenia, he was continued on dual ther-
py with ethambutol and clarithromycin for 6 months prior to con-
ideration for reimplantation. Pre-reimplantation CRP was normal at
.8 mg/L, and ESR was 49 mm/h. Although still on therapy, the right
nee synovial ﬂuid was aspirated prior to reimplantation and found
o be negative for mycobacterial growth.
Six weeks later, he underwent reimplantation. All 4 surgical tis-
ue samples from reimplantation remained negative for MAC. One of
cultures grew coagulase-negative staphylococci, which was consid-
red a contaminant. Pathology was negative for acute inﬂammation.
e continued ethambutol and clarithromycin for another 6 months,
o complete a total of 12 months. Then, he was placed on chronic
uppression with azithromycin 1200 mg orally once a week. Fifteen
onths later, he successfully underwent an elective contralateral
KA, again for degenerative joint disease. His multiple myelomawent
nto remission, precluding further chemotherapy. His methotrexate
or RA was switched to hydroxychloroquine. He continues to do well
t 7 years of follow-up after the 2-stage exchange of his MAC-infected
ight TKA.
iscussion
Nontuberculous mycobacteria (NTM) olecranon bursitis is very
are, with only 21 reported cases, 6 of which were due to MAC
Table 1). 38% of cases occurred in immunocompromised patients.
inor elbow trauma or bursa injection can provide a portal of entry
or NTM if contaminated with soil [2,3]. Most patients with NTM ole-
ranon bursitis typically present with mild pain that improves with
ultiple corticosteroid injections, but bursal swelling may worsen.
iagnosis is delayed more than 6 months in most cases. 13 out of
he 21 reported cases required surgical intervention followed by pro-
onged anti-mycobacterial therapy [2].This patient’s subsequent MAC infection of the TKA was also
nteresting. In general, the microorganisms causing PJI are S. au-
eus (31.0%), coagulase-negative Staphylococcus (20.2%), culture-
egative (15.8%), polymicrobial (7.4%), Streptococcus (5.8%), Entero-
occus (3.9%), fungi (2.3%), anaerobes (0.9%), and lastly mycobacteria
0.6%) [4]. Mycobacterial species previously reported to cause PJI in-
ludeM. tuberculosis, M. bovis, and the rapidly growing mycobacteria:
. abscessus, M. chelonae, M. fortuitum, M. kansasii, M. smegmatis, and
. wolinskyi. However, MAC PJI is relatively rare [5]. The pathogenesis
f his infection is unclear – whether it was contamination at surgery
r subsequent hematogenous spread. He had chronic respiratory tract
olonization, but there is no clear mechanism to explain how MAC
espiratory colonization could potentially lead to joint infection in his
ase. Currently, there are 2 known case reports of MAC PJI (Table 2)
5,6]. Because of the rarity of MAC PJI, optimal management is unde-
ned. A 3-drug regimen of a macrolide, ethambutol, and a rifamycin
s recommended for 6–12months, but accepted treatment guidelines
ave not been established [1]. Regarding reimplantation, treatment
ecisions must be extrapolated from the available literature on other
ycobacterial PJI’s. In a 1998 case series, only 2 out of 7 patients with
. tuberculosis PJI underwent reimplantation, one at 20 months and
ther at 30 months post-resection [7]. In a 2007 case series of PJI due
o rapidly growing mycobacteria (RGM), 2 patients underwent reim-
lantation (one at 3.5 months and one at 7.5 months post-resection)
nd required chronic antibiotic suppression [8].
ESR and CRP are helpful to assess clearance of bacterial infections
rior to reimplantation but may be unreliable in determining timing
f second-stage reimplantation in NTM PJIs [9]. Our patient’s ESR of
9 mm/h done one day prior to reimplantation may have been con-
ounded by his multiple myeloma and RA; however CRP had normal-
zed. In a 2007 case series of RGMPJI, themedian ESR at diagnosiswas
0.5mm/h, and themedian CRPwas 6mg/dL. In the two patientswho
nderwent reimplantation, ESR and CRP had normalized [8]. Synovial
uid WBC count less than 1102.5 cells/uL may be an adjunctive peri-
perative test but only has a sensitivity of 75% and speciﬁcity of 61%
nd has not been studied in NTM PJI [9].
Suppressive therapy is another important question. One pa-
ient with M. chelonae PJI underwent resection, reimplantation,
nd suppressive therapy with clarithromycin and moxiﬂoxacin. Two
atients with M. fortuitum PJI were able to retain their pros-
hesis and remained asymptomatic on suppressive regimens of
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Table 1
6 prior case reports of olecranon bursitis due to MAC, adapted with permission from Garrigues et al. 2009.
Age (years)/sex Symptoms Medical history Steroid use Time from symptom
onset to diagnosis
(months)
Antibiotics Treatment duration
(months)
Number of
surgeries
Outcome
58/male Drainage Colon carcinoma None 6 Rifampin 1 2 Resolved
49/female Drainage,
ulcer
Mixed connective tissue
disease
Oral 14 Rifampin,
ethambutol,
isoniazid
36 1 Recurrence
57/male Mild pain Psoriasis None >9 Ciproﬂoxacin,
rifampin,
clarithromycin
Not noted 1 Resolved
53/male Swelling None Oral 7 Rifampin,
ethambutol,
azithromycin
8 1 Resolved
61/male Swelling, pain Diabetes mellitus, atrial
ﬁbrillation
Intrabursal 1 Ethambutol,
clarithromycin
Not noted 1 Resolved
54/female Swelling, pain End-stage renal disease on
hemodialysis, congestive
heart failure, atrial
ﬁbrillation
Intrabursal 4 Not noted Not noted 1 Resolved
Table 2
2 prior case reports of prosthetic joint infection due to MAC.
Age/sex Symptoms Medical history Steroid use Time from symptom
onset to diagnosis
(months)
Antibiotics Treatment
duration
(months)
Number of surgeries Outcome
67/female Warmth, pain,
decreased
mobility
Left total hip arthroplasty,
systemic lupus, end-stage
renal disease, kidney
transplant, anal cancer
Oral Not speciﬁed Ethambutol,
rifabutin,
azithromycin
12 2 incisions &
drainages, 1
explant of
prosthesis, 1
reimplantation
Resolved
20/male Pain Bilateral hip replacements,
osteoarthritis, Perthes
disease, AIDS
None <1 month Ciproﬂoxacin,
clarithromycin,
rifampicin,
clofazimine
5 (died during
treatment)
1 hip aspiration, 1
resection
arthroplasty
Expired
R
[moxiﬂoxacin, trimethoprim-sulfamethoxazole and azithromycin and
levoﬂoxacin/trimethoprim-sulfamethoxazole, respectively. However,
suppressive therapy may not be feasible with other species such as
M. abscessus, which are often resistant to most oral antibiotics [8].
This patient’s MAC olecranon bursitis and PJI were separated by
approximately 4 years, suggesting long-term colonization. MAC has
been known to colonize the respiratory and gastrointestinal tract of
patients especially those with immune compromise such as AIDS or
those with structural lung disease, such as COPD or bronchiectasis.
Our patient was immunocompromised with his multiple myeloma
and treatment of seronegative RA [10–12]. Other risk factors for pul-
monary NTM colonization include white race, age greater than or
equal to 60 years, female sex, birth and residency in Canada for at
least 10 years. Our patient possesses the risk factors of white race
and age greater than 60 years and immune suppression for his long-
term colonization with MAC [12]. This patient’s MAC olecranon bur-
sitis, followed by a MAC PJI 4 years later, is a rare phenomenon and
likely related to chronic relatively asymptomatic respiratory MAC
colonization.
In summary, mycobacterial PJIs are very rare, and patients often
experience a delay in diagnosis. Mycobacterial cultures should be ob-
tained in immunocompromised patients with persistent symptoms
and negative bacterial cultures [2]. This is the seventh case report of
MAC olecranon bursitis and the third case report of aMAC PJI. This pa-
tient is unique, as he is the only known case of both MAC olecranon
bursitis and PJI occurring in the same patient. This case also high-
lights the rare risk of MAC PJI in immunocompromised patients who
may be colonized with MAC.
Learning points for clinicians
1. Obtain mycobacterial cultures for persistent join pain or swelling
despite empiric antibiotics, especially if the patient is immuno-
compromised.2. ESR, CRP, and synovial WBC count may be helpful to determine
timing of reimplantation for patients with PJI’s.
3. Discuss the option of long-term antibiotic suppression for pa-
tients with MAC PJI.
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